Novel fully human IgG1 targeting folate receptor α demonstrates antitumor efficacy driven by avidity rather than monovalent binding affinity

ATCC:

American Type Culture Collection

BSA:

Bovine Serum Albumin

ELISA:

Enzyme-linked immunosorbent assay

FACS:

Fluorescence-activated cell sorting

Fab:

Fragment antigen-binding

F(ab)2:

Divalent antibody fragment

FRα:

Folate receptor alpha

HBS-EP+:

Hepes-bufferred saline with surfactant 20

HRP:

Horseradish peroxidase

IgG:

Immunoglobulin G

Mab:

Monoclonal Antibody

MCK:

Multi-cycle kinetics

PBMC:

Peripheral blood mononuclear cells

PBS:

Phosphate-buffered saline

PIPE:

Polymerase Incomplete Primer Extension

POCC:

Primary ovarian cell cancer line

SDS-PAGE:

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

SEC:

Size exclusion chromatography

SCK:

Single-cycle kinetics

VH:

Heavy-chain variable

VL:

Light-chain variable

1. Nawaz, F. Z. & Kipreos, E. T. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol. Metab. 33 (3), 159–174 (2022).

   Google Scholar 

2. Scaranti, M., Cojocaru, E., Banerjee, S. & Banerji, U. Exploiting the folate receptor α in oncology. Nat. Rev. Clin. Oncol. 17 (6), 349–359 (2020).

   Google Scholar 

3. Cheung, A., Bax, H. J., Josephs, D. H., Tutt, A. N. & Karagiannis, S. N. Targeting folate receptor alpha for cancer treatment. Oncotarget 7 (32), 52553–52574 (2016).

   Google Scholar 

4. Frigerio, B., Bizzoni, C., Jansen, G., Matherly, L. H. & Figini, M. Folate receptors and transporters: Biological role and diagnostic/therapeutic targets in cancer and other diseases. J. Experimental Clin. Cancer Res. 38 (1), 125 (2019).

   Google Scholar 

5. Ornella, M. S. C. et al. Immunotherapy for peritoneal carcinomatosis: Challenges and prospective outcomes. Cancers 15 (8), 2383 (2023).

   Google Scholar 

6. Baydoun, M. et al. Folate receptor targeted photodynamic therapy: A novel way to stimulate Anti-Tumor immune response in intraperitoneal ovarian cancer. Int. J. Mol. Sci. 24 (14), 11288 (2023).

   Google Scholar 

7. Qi, J., Hymel, D., G Nelson, C., R Burke, T. & Rader, C. Conventional and chemically programmed asymmetric bispecific antibodies targeting folate receptor 1. Front. Immunol. 10, 1994 (2019).

   Google Scholar 

8. Young, O. et al. Folate receptor as a biomarker and therapeutic target in solid tumors. Curr. Probl. Cancer. 47 (1), 100917 (2023).

   Google Scholar 

9. Tamura, N. et al. Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma. Lung Cancer. 145, 152–157 (2020).

   Google Scholar 

10. Kumari, L. et al. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. J. Drug Target. 31 (9), 889–907 (2023).

    Google Scholar 

11. Schnoell, J. et al. Protein expression of folate receptor alpha in adenoid cystic carcinoma of the head and neck. Onco Targets Ther. 15, 531–538 (2022).

    Google Scholar 

12. Despierre, E. et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol. Oncol. 130 (1), 192–199 (2013).

    Google Scholar 

13. Crane, L. M. A. et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell. Oncol. (Dordr). 35 (1), 9–18 (2012).

    Google Scholar 

14. Miotti, S. et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer. 39 (3), 297–303 (1987).

    Google Scholar 

15. Frigerio, B., Montermini, M., Canevari, S. & Figini, M. Role of antibody engineering in generation of derivatives starting from MOv19 mab: 40 years of biological/therapeutic tools against folate receptor Alfa. Antib. Ther. 5 (4), 301–310 (2022).

    Google Scholar 

16. Matulonis, U. A. et al. Efficacy and safety of Mirvetuximab Soravtansine in patients with Platinum-Resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41 (13), 2436–2445 (2023).

    Google Scholar 

17. Moore, K. N. et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant ovarian cancer. N Engl. J. Med. 389 (23), 2162–2174 (2023).

    Google Scholar 

18. Dilawari, A. et al. FDA approval summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant ovarian cancer. Clin. Cancer Res. 29 (19), 3835–3840 (2023).

    Google Scholar 

19. Shah, P. et al. 431 First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer. J. Immunother. Cancer 9(Suppl 3): A461–A461. https://jitc.bmj.com/content/9/Suppl_2/A461 (2021).

20. Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G. & Hoogenboom, H. R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnol. (N Y). 9, 899–903 (1994).

    Google Scholar 

21. Figini, M. et al. Panning phage antibody libraries on cells: isolation of human fab fragments against ovarian carcinoma using guided selection. Cancer Res. 58 (5), 991–996 (1998).

    Google Scholar 

22. Figini, M. et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol. Immunother. 58 (4), 531–546 (2009).

    Google Scholar 

23. Zacchetti, A. et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J. Nucl. Med. 52 (12), 1938–1946 (2011).

    Google Scholar 

24. Coney, L. et al. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 54, 2448–2455 (1994).

    Google Scholar 

25. Casalini, P. et al. Unidirectional potentiation of binding between two anti-FBP mabs: evaluation of the involved mechanisms. J. Cell. Biochem. 58 (1), 47–55 (1995).

    Google Scholar 

26. Satta, A. et al. A bispecific antibody to link a TRAIL-Based antitumor approach to immunotherapy. Front. Immunol. 10, 2514 (2019).

    Google Scholar 

27. Bax, H. J. et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br. J. Cancer. 128 (2), 342–353 (2023).

    Google Scholar 

28. Ebel, W. et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 7, 6 (2007).

    Google Scholar 

29. Mazor, Y. et al. Enhancement of immune effector functions by modulating IgG’s intrinsic affinity for target antigen. PLoS ONE, 11 (6), 1–20 (2016).

30. Wang, R. et al. Antibody-Drug conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18 (1), 51 (2025).

    Google Scholar 

31. Evans, R. et al. Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting. Sci. Rep. 12 (1), 7677 (2022).

    Google Scholar 

32. Rudnick, S. I. et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71 (6), 2250–2259 (2011).

    Google Scholar 

33. Fujimori, K., Covell, D. G., Fletcher, J. E. & Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J. Nucl. Med. 31 (7), 1191–1198 (1990).

    Google Scholar 

34. van Osdol, W., Fujimori, K. & Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a ‘binding site barrier’. Cancer Res. 51 (18), 4776–4784 (1991).

    Google Scholar 

35. Bordeau, B. M., Yang, Y. & Balthasar, J. P. Transient competitive Inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy. Cancer Res. 81 (15), 4145–4154 (2021).

    Google Scholar 

36. Coliva, A. et al. 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol. Immunother. 54 (12), 1200–1213 (2005).

    Google Scholar 

37. Dodev, T. S. et al. A tool kit for rapid cloning and expression of Recombinant antibodies. Sci. Rep. 4, 5885 (2014).

    Google Scholar 

38. Frigerio, B. et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur. J. Cancer. 49 (9), 2223–2232 (2013).

    Google Scholar 

39. Tabatabaei, M. S. & Ahmed, M. Enzyme-Linked immunosorbent assay (ELISA). Methods Mol. Biol. 2508, 115–134 (2022).

    Google Scholar 

Download references

Author notes

1. Elena Pinto and Davide Tresoldi contributed equally to this work.

2. Delia Mezzanzanica and Mariangela Figini contributed equally to this work.

Authors and Affiliations

1. ANP 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy

   Elena Pinto, Davide Tresoldi, Valeria Arlotta, Elena Luison, Barbara Frigerio, Elisa Corsiero & Mariangela Figini

2. Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK

   Elisa Corsiero

3. Gynecologic Oncologic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy

   Francesco Raspagliesi

4. St. John’s Institute of Dermatology, School of Basic and Medical Biosciences and KHP Centre for Translational Medicine, King’s College London, Guy’s Hospital, London, UK

   Sophia N. Karagiannis

5. Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, UK

   Sophia N. Karagiannis

6. Segrate, Italy

   Silvana Canevari

7. Integrated Biology of Rare Tumors Unit, Dept. of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy

   Delia Mezzanzanica

Contributions

Mariangela Figini: conception and design of the study. Elena Luison, Davide Tresoldi, Valeria Arlotta, Elena Pinto: *in vitro* functional and biological characterization of AFRA hIgG1. Elena Luison, Valeria Arlotta, Elena Pinto: production and purification of the IgG and technical support *in vitro* experiments. Mariangela Figini, Delia Mezzanzanica, Silvana Canevari, Barbara Frigerio, Elena Luison, Valeria Arlotta, Elisa Corsiero, Francesco Raspagliesi: acquisition, analysis of data, interpretation of data and drafting the manuscript. Mezzanzanica Delia, Sophia Karagiannis, Silvana Canevari, Mariangela Figini: final revision of the manuscript and enhancement of its intellectual content. All authors reviewed the results and approved the final version of the manuscript.

Corresponding author

Correspondence to Mariangela Figini.

Competing interests

The authors declare no competing interests.

Ethics approval

I confirm that the use of the patients ascitic fluid cells has been approved by the ethical committee CET Lombardia 4; identificative number INT131/23.

Consent to participate

Ascitic fluid samples, collected during routine medical procedures, were made available for research purposes, in accordance with the institutional guidelines. Clinical details were recorded, and samples were assigned with a reference number to retain anonymity.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions